Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ascendis Pharma ADR TUBORG BOULEVARD 12 HELLERUP G7 2900 DNK

P: 45-7022-2244

Description:

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.

Key Statistics

Overview:

Market Capitalization, $K 5,733,528
Enterprise Value, $K 4,926,578
Shares Outstanding, K 56,965
Annual Sales, $ 9,200 K
Annual Net Income, $ -453,810 K
Last Quarter Sales, $ 6,560 K
Last Quarter Net Income, $ -86,540 K
60-Month Beta 0.66
% of Insider Shareholders 40.00%
Float, K 34,179
% Float 60.00%
Short Volume Ratio 0.76

Growth:

1-Year Return -40.19%
3-Year Return 4.64%
5-Year Return 177.66%
5-Year Revenue Growth 80.39%
5-Year Earnings Growth -190.53%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.54 on 08/10/22
Next Earnings Date 11/09/22
Earnings Per Share ttm -7.89
EPS Growth vs. Prev Qtr 37.90%
EPS Growth vs. Prev Year 48.84%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ASND Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -48.92%
Return-on-Assets % -31.26%
Profit Margin % -4,932.72
Net Margin % N/A
Debt/Equity 0.69
Price/Sales 643.00
Price/Cash Flow N/A
Price/Book 9.15
Book Value/Share 11.36
Interest Coverage -97.11
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar